Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED.WR | N.MMED.WS | N.MMED | N.MMED.WA

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Bullboard Posts
Post by Canucklehead80on Jan 11, 2013 4:10am
206 Views
Post# 20824252

Auguries - January 10, 2013

Auguries - January 10, 2013

Auguries - January 10, 2013
Liquefaction
Kevin Michael Grace


Liquefaction, Japan 1964: All it takes is a shock.
Gold was up (at press time) $15.90 (+1%) for the fortnight to $1,664.70, and silver was up $0.18 (+0.6%) to $30.18. Gold fell $24.10 Thursday (-1.4%), a development Bloomberg attributed to “Federal Reserve policymakers sa[ying] they probably will end their $85-billion monthly US bond purchases sometime in 2013.” No, the Federal Open Market Committee said no such thing, as its minutes prove, minutes which the BBC, unlike Bloomberg, managed to report accurately.

In any event, gold finished 2012 up for the twelfth year in a row, gaining 7% measured in US dollars. As for 2013, Ambrose Evans-Pritchard writes January 1, “The US, Japan, Britain, as well as the Swiss, Scandies and a string of states around the world, are actively driving down their currencies or imposing caps…. The side-effects of this currency warfare—or ‘beggar-thy-neighbour’ policy, as it was known in the 1930s—is an escalating leakage of monetary stimulus into the global system.”

Read more about gold prices here.

Bullboard Posts